Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children - 14/04/20
, Amy S. Paller, MD, MS a, c, d, ⁎ Abstract |
Background |
Accurately documenting pediatric atopic dermatitis (AD) severity is important, but research tools, such as Eczema Area and Severity Index (EASI), are too time consuming for clinical settings. Product of the Physician Global Assessment and affected percentage of body surface area (PGA×BSA) is a new, rapid measure of psoriasis severity.
Objective |
To evaluate an Investigator Global Assessment and body surface area product (IGA×BSA) as an easy-to-use severity measure for pediatric AD.
Methods |
Patient-reported and objective disease severity measures were collected from 195 caretaker/child dyads (child age range, 5-17 years) with almost clear (Validated Investigator Global Assessment for AD [vIGA] of 1) to severe (vIGA of 4) AD. Data were assessed with Spearman coefficients and plots. Severity strata were proposed by using an anchoring approach based on the EASI.
Results |
IGA×BSA correlates better with the EASI than IGA alone (r = 0.924 vs r = 0.757, P < .001). Bland-Altman plot indicates high and consistent agreement between IGA×BSA and the EASI. Suggested severity strata for IGA×BSA are 0-30, mild; 30.1-130, moderate; and 130.1-400, severe (κ = 0.760).
Limitations |
The patient cohort was predominantly from the midwestern United States.
Conclusions |
IGA×BSA (using the vIGA) is a simple measure that correlates well with the EASI in patients with mild to severe pediatric AD. Future work is needed to affirm reliability across IGA scales and responsiveness to change.
Le texte complet de cet article est disponible en PDF.Key words : adolescent, disease severity, eczema, pediatric, pruritus, quality of life
Abbreviations used : AD, BSA, CDLQI, DLQI, EASI, IGA, IGA×BSA, NRS, oSCORAD, PASI, PGA, PGA×BSA, POEM, SCORAD, vIGA
Plan
| Drs Paller and Fishbein are cosenior authors. |
|
| Funding sources: Supported in part by the National Institutes of Health's National Center for Advancing Translational Sciences UL1TR001422 and NUCATS U19 069526. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Approved by the Lurie Children's IRB (2016-201). |
Vol 82 - N° 5
P. 1187-1194 - mai 2020 Retour au numéro
Article précédent
- Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative
- Yael A. Leshem, Joanne R. Chalmers, Christian Apfelbacher, Masutaka Furue, Louise A.A. Gerbens, Cecilia A.C. Prinsen, Jochen Schmitt, Phyllis I. Spuls, Kim S. Thomas, Hywel C. Williams, Eric L. Simpson, Harmonising Outcome Measures for Eczema (HOME) initiative
- Outcomes in intermediate-risk squamous cell carcinomas treated with Mohs micrographic surgery compared with wide local excision
- David D. Xiong, Brandon T. Beal, Vamsi Varra, Marla Rodriguez, Hannah Cundall, Neil M. Woody, Allison T. Vidimos, Shlomo A. Koyfman, Thomas J. Knackstedt
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?